Summary of Research
- Recent analysis of FDA Adverse Events Reporting System (FAERS) data revealed six out of the top 10 alopecia areata treatments were monoclonal antibodies.
- Males were more likely than females to report alopecia with dupilumab or adalimumab, addressing a gap in establishing causal connections between drugs and alopecia areata.
- The study identified 1,331 alopecia areata cases linked to medication adverse events, with individuals aged 42 to 64 years accounting for 46.7% of cases, and older females having greater odds of alopecia development than males.
- Future research is needed to control for gender-based drug use variations and acknowledge limitations in scope, focusing on medication-related cases reported by the general public on FAERS.